NaCl (0,9%)

DRUG4 trials

Sponsors

GWT-TUD GmbH, Thomas Engstrom, Assistance Publique - Hôpitaux de Paris, University Hospital of Split

Conditions

Autism Spectrum DisorderEmergence DeliriumIron DeficiencyRemimazolamSTEMI - ST Elevation Myocardial InfarctionTonsillectomyType 2 Diabetes Mellitus

Phase 1

Remimazolam for Emergence Delirium Prevention in Children Undergoing Tonsillectomy

CompletedNCT07704437

University Hospital of SplitEmergence Delirium, Remimazolam, Tonsillectomy

Start: 2024-04-01End: 2026-05-05Updated: 2026-07-15

Phase 2

Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders

Not yet recruitingNCT07589842

Assistance Publique - Hôpitaux de ParisAutism Spectrum Disorder

Start: 2026-10-01End: 2029-08-01Target: 22Updated: 2026-05-15

Phase 3

Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency

CompletedNCT01513369

GWT-TUD GmbHIron Deficiency, Type 2 Diabetes Mellitus

Start: 2012-08-31End: 2019-04-30Target: 152Updated: 2021-02-04

Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial

RecruitingNCT07478003

Thomas EngstromSTEMI - ST Elevation Myocardial Infarction

Start: 2026-04-20End: 2036-04-01Target: 5204Updated: 2026-04-23

Related Papers

Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

2017-11-139 citations